171results about "Bacteria peptides" patented technology

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gulae in a subject, and uses thereof.

Disclosed are fusion proteins that can be manufactured at low cost, in a short cycle, and in high yield. The coding nucleic acid, in vitro synthesis system, and method for manufacturing the fusion protein are also disclosed. The fusion protein is used to kill target cells and comprises an effector portion A containing a toxin molecule, a guide vector portion B that binds to a target of the target cell and is derived from an antibody or cytokine, and a first linker L1 that links the effector portion A and the guide vector portion B, wherein the first linker L1 comprises at least three amino acid residues; preferably, the effector portion A, the first linker L1, and the guide vector portion B are linked from the N-terminus to the C-terminus in the A-L1-B or B-L1-LA direction.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

The present invention relates to a DNA construct and a bacterial strain into which a recombinant vector containing the DNA construct has been introduced. The DNA construct of the present invention has the effect of preventing and treating cancer by expressing an anti-cancer gene operably linked downstream of a first promoter and a second promoter in a host bacterial strain or cell. Furthermore, the DNA construct of the present invention allows the expression of an anti-cancer protein at an appropriate dose for cancer treatment by controlling the presence or absence of doxycycline treatment.

It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.

The application discloses a Campylobacter-specific protein antibody, an antibody-coupled magnetic bead and application. The antibody is a monoclonal antibody 1A10 and a monoclonal antibody 3D9, the monoclonal antibody 1A10 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 1A10 are shown in SEQ ID NO: 7 and 8 respectively; the monoclonal antibody 3D9 comprises a light chain variable region and a heavy chain variable region, the amino acid sequences of the light chain variable region and the heavy chain variable region of the monoclonal antibody 3D9 are shown in SEQ ID NO: 9 and 10 respectively. The antibody-coupled magnetic bead is coupled by the monoclonal antibody 1A10, the monoclonal antibody 3D9 and activated carboxyl magnetic beads respectively. The antibody-coupled magnetic bead can specifically enrich Campylobacter, has high enrichment efficiency, simple enrichment operation, can be applied to metabolic product analysis of Campylobacter, and can be used for qualitative and quantitative analysis of the Campylobacter.

The application provides a coenzyme Q10-producing genetically engineered bacterium and application thereof.

The invention belongs to the technical field of biological medicines, and discloses an engineered bacterium for in-situ expression of a microtubule inhibition protein in a tumor and application of the engineered bacterium. The engineering bacteria are formed by constructing microtubule inhibition protein genes to an expression vector and finally transferring the expression vector into bacteria. The engineering bacterium can be colonized in a tumor microenvironment in a targeted manner, expresses microtubule inhibition protein, effectively inhibits tumor cells and remarkably inhibits solid tumor growth, and is excellent in safety.

A high-purity yeast protein and a preparation method therefor, wherein the method comprises the following steps: inoculating an activated yeast strain into a liquid seed culture medium, culturing same in a shaker, then inoculating same into a fermentation culture medium for culturing, and centrifuging and washing same to obtain a yeast strain; preparing the yeast strain into a suspension solution, and performing a heat treatment to collect a precipitate; preparing the precipitate into a suspension, adding 5-50 U / mL of dextranase and 5-50 U / mL of cellulase at a pH of 5.0-7.0 and 30-60°C, and performing enzymatic hydrolysis to obtain a first enzymatic hydrolysate; adding a non-ionic solubilizer to the first enzymatic hydrolysate at a certain pH, and incubating the resulting mixure at a certain temperature to obtain a second enzymatic hydrolysate; and subjecting the second enzymatic hydrolysate to solid-liquid separation, washing and drying to obtain a high-purity yeast protein. The method reduces the possibility of protein denaturation. The final yeast protein product has a low dietary fiber content, a high branched-chain amino acid content and a high protein content, and exhibits good nutritional value and processing characteristics.

It provides a vaccine platform that can be tailored to target any tumor type and appropriately stimulates the expansion of specific anti-tumor immune cells. [Solution] Provided are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., a tumor cell, a tumor antigen, a virus, or a viral antigen). The self-assembling pharmaceutical compositions can further comprise an immunotherapy (e.g., an anti-PD-1 antibody). Also provided are methods of using these pharmaceutical compositions for preventing and / or treating cancer or inducing an immune response. Also provided are methods of using the self-assembling pharmaceutical compositions in combination with immunotherapy (e.g., an anti-PD-1 antibody).

The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.

The present invention relates to a combination of a first vaccine containing a non-replicating immunogen of Erysipelothrix rhusiopathiae and a non-replicating immunogen of porcine parvovirus, and a second vaccine containing a non-replicating immunogen of Leptospira bacteria, for use in the prophylactic treatment of pigs against Erysipelothrix rhusiopathiae infection, porcine parvovirus infection, and Leptospira bacteria infection, by injecting the first vaccine and the second vaccine separately into the dermis at a first injection site and a second injection site, respectively, in association with each other.

[Problem] To provide: a linear inulin synthesizing bacterium of species closely related to the genus Bacillus, the bacterium being characterized in that a branched inulin synthase gene or a specific branched inulin synthase-like gene is deleted or inactivated and an inulosucrase gene or a specific inulosucrase-like gene is carried; a method for producing linear inulin using the linear inulin synthesizing bacterium; and others. [Solution] Only linear inulin can be produced by deleting or mutating the whole or a part of BI gene in an inulin synthesizing bacterium to produce a ΔBI inulin synthesizing strain in which BI enzyme has been deleted or inactivated, and then allowing a culture supernatant of the produced ΔBI inulin synthesizing strain to act on sucrose.

The present disclosure relates to a microorganism that fixes carbon dioxide, presenting a new strategy capable of contributing to achieving carbon neutrality in bioprocesses through development of a CO2 fixing yeast using S. cerevisiae, wherein, to address the redox imbalance problem and increase CO2 fixation efficiency, a form-I RuBisCO-based CO2 fixation pathway was established in a xylose isomerase-based xylose metabolic strain, the fermentation rate and productivity were remarkably improved by deleting the endogenous reductase genes GRE3 and YPR1, which induce xylitol accumulation, resulting in a significant increase in a yield of ethanol production along with efficient CO2 fixation, the finally developed SJ11 YΔGΔ strain had significantly reduced xylitol accumulation, greatly improved fermentation rate, and maximized CO2 fixation efficiency and ethanol productivity compared to existing strains.

The present invention relates to novel oligomeric pore constructs derived from oligomeric translocases and monomers capable of forming transmembrane protein pores and their uses in analyte detection and characterisation.

This invention discloses an anti-phage system based on ESCRT-III and its applications, relating to the field of biotechnology. This invention utilizes the coding genes for two structural proteins of the Hoda_Snf7_1 and Hoda_Snf7_2 from the Hoda archaea ESCRT-III. Hoda_ snf7_1 and Hoda_snf7_2 This invention is applied to antiphage systems. Compared with existing technologies, the main advantages of the antiphage system of this invention are: (1) it consists of only two genes, making system construction simple and quick; (2) it is composed of structural proteins, making it less prone to losing antiphage activity due to gene mutations; (3) it has a broad-spectrum antiphage effect; and (4) it does not affect the normal growth of host bacteria. This system expands the understanding of antiphage systems and provides new ideas and technical means for preventing and controlling phage contamination in industrial microbial production processes.

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gingivalis in a subject, and uses thereof.

Methods for purifying a target protein using continuous countercurrent downstream processing are provided herein. Methods for purifying a target protein using continuous countercurrent affinity nanoparticle dialysis are also provided herein.

Plasmid-host systems are provided that allow for maintenance of the plasmid independent of antibiotic selection.

Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be selected from a hinge region of Lachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.

A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.

The present invention provides a chimeric or fusion protein for inducing an immune response to P. gulae, the protein comprising a first polypeptide and a second polypeptide, wherein: A) the first polypeptide comprises or consists of an amino acid sequence of the active site of an Arg- or Lys-gingipain of P. gulae, or a sequence that is at least 80% identical thereto; and B) the second polypeptide comprises or consists of: the amino acid sequence of a DUF2436 domain of a P. gulae Arg- or Lys-gingipain; and the amino acid sequence of an adhesin domain of an Arg- or Lys-gingipain of P. gulae.

A Cas12 RNP complex comprising: a first fusion protein comprising an extracellular vesicle (EV) polypeptide and a Cas12 protein; and a circular crRNA (CRISPR RNA) comprising: a spacer sequence, a dire

This invention relates to a botulinum toxin A1 precursor molecule, a nucleic acid molecule, an engineered bacterium, a method for preparing the same, and a method for preparing natural botulinum toxin A using the precursor molecule. The precursor molecule comprises a light chain and a heavy chain, and a linker region connecting the light and heavy chains. The amino acid sequence of the precursor molecule is shown in SEQ ID NO. 4. The light chain is the amino acid sequence from position 1 to position 444 of natural botulinum toxin A, as shown in SEQ ID NO. 5. The heavy chain sequence is the amino acid sequence from position 449 to position 1296 of natural botulinum toxin A, as shown in SEQ ID NO. 6. The amino acid sequence of the linker region is shown in SEQ ID NO. 11. This invention provides a safe process, and the resulting recombinant botulinum toxin not only has a sequence identical to the natural botulinum toxin active protein but also exhibits high activity, providing a low-cost, high-activity botulinum toxin product for clinical use.

The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating cancers and infections. An example method entails administering to the patient an effective amount of a composition comprising 1 × 107 to 500 × 107 intact, stabilized and substantially non-viable E. coli cells which have been treated in such a way as to result in about 70% to 99% reduction of lipopolysaccharide (LPS)-associated endotoxin activity when measured by the Limulus Amebocyte Lysate (LAL) assay as compared to untreated, wild-type E. coli cells, and wherein the composition contains 124 to 62000 endotoxin units (EU) of LPS.

The present invention provides a carrier for affinity chromatography that maintains high immunoglobulin binding capacity and alkali resistance. An immunoglobulin-binding protein comprising at least one modified immunoglobulin-binding domain that is a polypeptide consisting of an amino acid sequence that is an amino acid sequence of an immunoglobulin-binding domain selected from the group consisting of a B domain, a Z domain, a C domain, and variants thereof of staphylococcal protein A, with at least one amino acid residue inserted between positions corresponding to positions 3 and 4 of the amino acid sequence of the B domain, the Z domain, or the C domain.

A process for generating a final product comprising or consisting of a purified allergenic extract, comprising: (A) providing a crude allergenic extract, wherein the crude allergenic extract is obtained by isolation from a biological sample; (B) optionally, purifying the crude extract to obtain a purified crude extract, wherein the purifying step comprises: (B1) filtering the crude product to remove the natural microbial load with respect to the biological sample; (C) optionally, purifying the crude extract or the purified crude extract to obtain a purified extract, wherein the purifying step comprises: (C1) filtering the crude extract or the purified crude extract to remove impurities having a molecular weight of less than 5,000 Da. The process is characterized in that it comprises an ultrafiltration step for viruses which is functional for obtaining a final product which comprises or consists of a purified extract of allergens and which is substantially free of viruses and / or mycoplasmas. The present application also relates to a product for medical or diagnostic use, comprising one or more allergen extracts which are natural with respect to the starting biological sample or which are substantially free of viruses and / or mycoplasmas resulting from any external contamination.

The present disclosure relates to a microorganism comprising a heterologous fructokinase and a non-PTS sugar uptake factor, and a method for producing an L-amino acid using same.